Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C

Kawagishi, Naoki; Suda, Goki; Yamamoto, Yoshiya et al.

Viruses-Basel, 2023, 15(1), 181

Permalink : https://hdl.handle.net/2115/88804

このアイテムのアクセス数:485件（2026-10-18 12:52 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.3390/v15010181     110

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/88804
タイトル
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
著者
Kawagishi, Naoki ; Suda, Goki ; Yamamoto, Yoshiya ; Baba, Masaru ; Furuya, Ken ; Maehara, Osamu ; Ohnishi, Shunsuke ; Yoshida, Sonoe ; Fu, Qingjie ; Yang, Zijian ; Hosoda, Shunichi ; Tokuchi, Yoshimasa ; Kitagataya, Takashi ; Ohara, Masatsugu ; Suzuki, Kazuharu ; Nakai, Masato ; Sho, Takuya ; Natsuizaka, Mitsuteru ; Ogawa, Koji ; Sakamoto, Naoya
著者名
Kawagishi, Naoki
e-Rad_Researcher
20447460
著者名
Suda, Goki
著者名
Yamamoto, Yoshiya
著者名
Baba, Masaru
著者名
Furuya, Ken
著者名
Maehara, Osamu
著者名
Ohnishi, Shunsuke
著者名
Yoshida, Sonoe
著者名
Fu, Qingjie
著者名
Yang, Zijian
著者名
Hosoda, Shunichi
著者名
Tokuchi, Yoshimasa
著者名
Kitagataya, Takashi
著者名
Ohara, Masatsugu
著者名
Suzuki, Kazuharu
著者名
Nakai, Masato
著者名
Sho, Takuya
著者名
Natsuizaka, Mitsuteru
著者名
Ogawa, Koji
著者名
Sakamoto, Naoya
言語
英語
キーワード
hepatitis C virus
direct-acting antiviral
angiopoietin-2
hepatocellular carcinoma
recurrence
発行日
2023-01
出版者
MDPI
収録物名
Viruses-Basel
巻(号)
15(1)
ページ
181
抄録
Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014-2020 were screened and evaluated for HCC occurrence or recurrence every three-six months. Multivariate Cox regression analysis revealed that age >= 75 years (HR: 2.92, 95% CI: 1.34-6.33; p = 0.007) and baseline Ang2 level >= 464 pg/mL (HR: 2.75, 95% CI: 1.18-6.37; p = 0.019) were significantly associated with HCC occurrence after DAA therapy. A high or low risk of HCC after DAA therapy could be distinguished by the combination of age and baseline Ang2 level. The cumulative incidences of de-novo HCC at two and four years were 0.8% and 3.8% in the low-risk group and 22.6% and 27.1% in the high-risk group, respectively. Baseline Ang2 level >= 402 pg/mL was significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs (HR: 3.68). In conclusion, serum Ang2 levels can predict HCC occurrence and recurrence after successful HCV eradication by DAAs.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.3390/v15010181